Compare $APRE vs $LGVN | Chartloom

Compare

$APRE vs $LGVN

Aprea Therapeutics Inc · Longeveron Inc

APRE

Aprea Therapeutics Inc

LGVN

Longeveron Inc

Compare $APRE vs $LGVN

Comparing Aprea Therapeutics Inc and Longeveron Inc

APREAprea Therapeutics Inc

LGVNLongeveron Inc

APREAprea Therapeutics Inc

Market cap

$7M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-99.4%

YTD performance

-29.1%

52W performance

-57.8%

FCF yield

-162.8%

LGVNLongeveron Inc

Market cap

$78M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

64.70x

Rev growth (TTM)

-42.7%

YTD performance

-58.2%

52W performance

-73.3%

FCF yield

-26.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

APRE

LGVN

Detailed metrics comparison

APRE

Aprea Therapeutics Inc

LGVN

Longeveron Inc

Market Cap

APRE$7M

LGVN$78M

Enterprise Value

APRE$-34M

LGVN$68M

Price

APRE$0.60

LGVN$2.48

P/E Ratio

APREN/A

LGVNN/A

P/S Ratio

APRE1,438.94x

LGVN66.02x

EV/Sales

APRE-6,490.56x

LGVN57.53x

EV/EBITDA

APRE0.00x

LGVN0.00x

P/B Ratio

APRE0.22x

LGVN0.79x

P/FCF Ratio

APREN/A

LGVNN/A

EV/FCF

APRE2.77x

LGVN-3.30x

PEG Ratio

APREN/A

LGVNN/A

Forward P/E (NTM)

APREN/A

LGVNN/A

Forward P/S (NTM)

APREN/A

LGVN64.70x

Revenue (TTM)

APRE$5K

LGVN$1M

Revenue Growth (YoY)

APRE-99.4%

LGVN-42.7%

Forward Rev Growth

APRE445.8%

LGVN398.7%

Gross Margin (TTM)

APRE0.0%

LGVN69.8%

Operating Margin (TTM)

APRE0.0%

LGVN0.0%

EBITDA Margin (TTM)

APRE-253869.2%

LGVN-1907.3%

Net Margin (TTM)

APRE-236676.9%

LGVN-1977.6%

FCF Margin (TTM)

APRE-234296.2%

LGVN-1742.1%

Net Income (TTM)

APRE$-12M

LGVN$-23M

FCF (TTM)

APRE$-12M

LGVN$-21M

EPS (TTM)

APRE-$0.23

LGVN-$7.48

ROE (TTM)

APRE-4630.0%

LGVN-22319.0%

ROA (TTM)

APRE-4097.0%

LGVN-15020.0%

ROIC (TTM)

APRE-4630.0%

LGVN-22319.0%

Cash

APRE$41M

LGVN$10M

Debt

APRE$0

LGVN$0

Net Cash/Debt

APRE$41M

LGVN$10M

Current Ratio (TTM)

APRE13.55x

LGVN2.63x

Quick Ratio (TTM)

APRE13.33x

LGVN2.35x

Debt/Equity (TTM)

APRE0.00x

LGVN0.00x

Debt/Assets (TTM)

APRE0.0%

LGVN0.0%

Interest Coverage (TTM)

APREN/A

LGVNN/A

Net Debt/EBITDA (TTM)

APRE0.00x

LGVN0.00x

Beta

APRE-1.23

LGVN0.85

52W Performance

APRE-57.8%

LGVN-73.3%

YTD Performance

APRE-29.1%

LGVN-58.2%

% from 52W High

APRE-64.2%

LGVN-79.8%

% from 52W Low

APRE10.3%

LGVN7.8%

Asset Turnover (TTM)

APRE0.02x

LGVN0.08x

FCF Yield (TTM)

APRE-162.8%

LGVN-26.4%

Earnings Yield (TTM)

APRE-164.5%

LGVN-30.0%

Dividend Yield (TTM)

APREN/A

LGVNN/A

Rule of 40

APRE-234,395.5

LGVN-1,784.9

EV/GP/RG

APREN/A

LGVN40.37

Ticker research

View APRE research View LGVN research

Metric	APRE Aprea Therapeutics Inc	LGVN Longeveron Inc
Market & Valuation
Market Cap	$7M	$78M
Enterprise Value	$-34M	$68M
Price	$0.60	$2.48
P/E Ratio	N/A	N/A
P/S Ratio	1,438.94x	66.02x
EV/Sales	-6,490.56x	57.53x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.22x	0.79x
P/FCF Ratio	N/A	N/A
EV/FCF	2.77x	-3.30x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	64.70x
Revenue & Growth
Revenue (TTM)	$5K	$1M
Revenue Growth (YoY)	-99.4%	-42.7%
Forward Rev Growth	445.8%	398.7%
Profitability
Gross Margin (TTM)	0.0%	69.8%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-253869.2%	-1907.3%
Net Margin (TTM)	-236676.9%	-1977.6%
FCF Margin (TTM)	-234296.2%	-1742.1%
Net Income (TTM)	$-12M	$-23M
FCF (TTM)	$-12M	$-21M
EPS (TTM)	-$0.23	-$7.48
ROE (TTM)	-4630.0%	-22319.0%
ROA (TTM)	-4097.0%	-15020.0%
ROIC (TTM)	-4630.0%	-22319.0%
Financial Health
Cash	$41M	$10M
Debt	$0	$0
Net Cash/Debt	$41M	$10M
Current Ratio (TTM)	13.55x	2.63x
Quick Ratio (TTM)	13.33x	2.35x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-1.23	0.85
52W Performance	-57.8%	-73.3%
YTD Performance	-29.1%	-58.2%
% from 52W High	-64.2%	-79.8%
% from 52W Low	10.3%	7.8%
Efficiency & Yields
Asset Turnover (TTM)	0.02x	0.08x
FCF Yield (TTM)	-162.8%	-26.4%
Earnings Yield (TTM)	-164.5%	-30.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-234,395.5	-1,784.9
EV/GP/RG	N/A	40.37
Ticker research	View APRE research	View LGVN research

Valuation

P/S Ratio

LGVN

66.02x

APRE

1,438.94x

EV/FCF

LGVN

-3.30x

APRE

2.77x

Growth & revenue

Revenue Growth TTM

LGVN

-42.7%

APRE

-99.4%

Forward Revenue Growth

APRE

445.8%

LGVN

398.7%

Profitability & performance

Gross Margin

LGVN

69.8%

APRE

0.0%

ROE

APRE

-4630.0%

LGVN

-22319.0%

FCF Yield %

LGVN

-26.4%

APRE

-162.8%

52-Week Performance

APRE

-57.8%

LGVN

-73.3%

Detailed metrics comparison

APRE

Aprea Therapeutics Inc

LGVN

Longeveron Inc

Market Cap

APRE$7M

LGVN$78M

Enterprise Value

APRE$-34M

LGVN$68M

Price

APRE$0.60

LGVN$2.48

P/E Ratio

APREN/A

LGVNN/A

P/S Ratio

APRE1,438.94x

LGVN66.02x

EV/Sales

APRE-6,490.56x

LGVN57.53x

EV/EBITDA

APRE0.00x

LGVN0.00x

P/B Ratio

APRE0.22x

LGVN0.79x

P/FCF Ratio

APREN/A

LGVNN/A

EV/FCF

APRE2.77x

LGVN-3.30x

PEG Ratio

APREN/A

LGVNN/A

Forward P/E (NTM)

APREN/A

LGVNN/A

Forward P/S (NTM)

APREN/A

LGVN64.70x

Revenue (TTM)

APRE$5K

LGVN$1M

Revenue Growth (YoY)

APRE-99.4%

LGVN-42.7%

Forward Rev Growth

APRE445.8%

LGVN398.7%

Gross Margin (TTM)

APRE0.0%

LGVN69.8%

Operating Margin (TTM)

APRE0.0%

LGVN0.0%

EBITDA Margin (TTM)

APRE-253869.2%

LGVN-1907.3%

Net Margin (TTM)

APRE-236676.9%

LGVN-1977.6%

FCF Margin (TTM)

APRE-234296.2%

LGVN-1742.1%

Net Income (TTM)

APRE$-12M

LGVN$-23M

FCF (TTM)

APRE$-12M

LGVN$-21M

EPS (TTM)

APRE-$0.23

LGVN-$7.48

ROE (TTM)

APRE-4630.0%

LGVN-22319.0%

ROA (TTM)

APRE-4097.0%

LGVN-15020.0%

ROIC (TTM)

APRE-4630.0%

LGVN-22319.0%

Cash

APRE$41M

LGVN$10M

Debt

APRE$0

LGVN$0

Net Cash/Debt

APRE$41M

LGVN$10M

Current Ratio (TTM)

APRE13.55x

LGVN2.63x

Quick Ratio (TTM)

APRE13.33x

LGVN2.35x

Debt/Equity (TTM)

APRE0.00x

LGVN0.00x

Debt/Assets (TTM)

APRE0.0%

LGVN0.0%

Interest Coverage (TTM)

APREN/A

LGVNN/A

Net Debt/EBITDA (TTM)

APRE0.00x

LGVN0.00x

Beta

APRE-1.23

LGVN0.85

52W Performance

APRE-57.8%

LGVN-73.3%

YTD Performance

APRE-29.1%

LGVN-58.2%

% from 52W High

APRE-64.2%

LGVN-79.8%

% from 52W Low

APRE10.3%

LGVN7.8%

Asset Turnover (TTM)

APRE0.02x

LGVN0.08x

FCF Yield (TTM)

APRE-162.8%

LGVN-26.4%

Earnings Yield (TTM)

APRE-164.5%

LGVN-30.0%

Dividend Yield (TTM)

APREN/A

LGVNN/A

Rule of 40

APRE-234,395.5

LGVN-1,784.9

EV/GP/RG

APREN/A

LGVN40.37

Ticker research

View APRE research View LGVN research

Metric	APRE Aprea Therapeutics Inc	LGVN Longeveron Inc
Market & Valuation
Market Cap	$7M	$78M
Enterprise Value	$-34M	$68M
Price	$0.60	$2.48
P/E Ratio	N/A	N/A
P/S Ratio	1,438.94x	66.02x
EV/Sales	-6,490.56x	57.53x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.22x	0.79x
P/FCF Ratio	N/A	N/A
EV/FCF	2.77x	-3.30x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	64.70x
Revenue & Growth
Revenue (TTM)	$5K	$1M
Revenue Growth (YoY)	-99.4%	-42.7%
Forward Rev Growth	445.8%	398.7%
Profitability
Gross Margin (TTM)	0.0%	69.8%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-253869.2%	-1907.3%
Net Margin (TTM)	-236676.9%	-1977.6%
FCF Margin (TTM)	-234296.2%	-1742.1%
Net Income (TTM)	$-12M	$-23M
FCF (TTM)	$-12M	$-21M
EPS (TTM)	-$0.23	-$7.48
ROE (TTM)	-4630.0%	-22319.0%
ROA (TTM)	-4097.0%	-15020.0%
ROIC (TTM)	-4630.0%	-22319.0%
Financial Health
Cash	$41M	$10M
Debt	$0	$0
Net Cash/Debt	$41M	$10M
Current Ratio (TTM)	13.55x	2.63x
Quick Ratio (TTM)	13.33x	2.35x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-1.23	0.85
52W Performance	-57.8%	-73.3%
YTD Performance	-29.1%	-58.2%
% from 52W High	-64.2%	-79.8%
% from 52W Low	10.3%	7.8%
Efficiency & Yields
Asset Turnover (TTM)	0.02x	0.08x
FCF Yield (TTM)	-162.8%	-26.4%
Earnings Yield (TTM)	-164.5%	-30.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-234,395.5	-1,784.9
EV/GP/RG	N/A	40.37
Ticker research	View APRE research	View LGVN research